Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT03262935 is registered in ClinicalTrials.gov with Byondis B.V. as lead sponsor.

NCT NCT03262935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03262935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Byondis B.V.
Phase
Phase 3
Overall status
Completed
Start date
December 15, 2017
Completion date
June 30, 2022
Enrollment
437 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer